Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 1 20 versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 1 20 versus NORINYL 1 80 21 DAY.
AUROVELA 1/20 vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin (FSH, LH) release, inhibiting ovulation, altering cervical mucus, and reducing endometrial receptivity.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
One tablet orally once daily at the same time each day for 21 days, followed by 7 placebo tablets. Each tablet contains ethinyl estradiol 0.02 mg and norethindrone acetate 1 mg.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Norethindrone: ~8–11 hours (terminal); ethinyl estradiol: ~13–19 hours (terminal). Steady-state achieved within 5–7 days.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Renal (30–40% as metabolites, <5% unchanged); biliary/fecal (40–60% as metabolites).
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive